Arundic acid

Drug Profile

Arundic acid

Alternative Names: Arocyte Injection; Cereact Capsule; MK-0724; ONO-2506; ONO-2506PO; Proglia®

Latest Information Update: 18 Mar 2010

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Developer Merck & Co; Ono Pharmaceutical
  • Class Neuroprotectants; Nootropics; Octanoic acids; Small molecules
  • Mechanism of Action Astrocyte modulators; Cyclo-oxygenase 2 inhibitors; Free radical scavengers; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease; Stroke

Most Recent Events

  • 01 Nov 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Alzheimer's disease pharmacodynamics section
  • 01 Nov 2006 This compound is still in active development for Alzheimer's disease in Japan
  • 18 Aug 2006 Commencement of phase-II clinical trials in Stroke planned in North America (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top